相关实验视频
Updated: Jun 22, 2025
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.9K
[患有CD5+扩散大B细胞淋巴瘤的患者的临床特征和预后]
Xiu-Juan Huang1, Jian Yang2, Xiao-Fang Wei3
1Department of Hematology, Shaanxi Provincial People's Hospital, Xi'an 710068, Shaanxi Province, China.
Zhongguo shi yan xue ye xue za zhi
|June 27, 2024
概括
与CD5阴性DLBCL相比,CD5阳性扩散性大B细胞淋巴瘤 (DLBCL) 表示预后较差. 这种亚型在老年女性中更为普遍,并且与较高的国际预后指数得分有关.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种异质性疾病.
- CD5表达是一种可以进一步分层DLBCL亚型的标记物.
- 了解DLBCL中CD5表达的临床意义对于预后至关重要.
研究的目的:
- 为了研究CD5阳性 (CD5+) DLBCL的临床特征.
- 分析DLBCL患者CD5表达的预后影响.
- 为了确定CD5+和CD5-DLBCL亚型之间的差异.
主要方法:
- 来自161名DLBCL患者的临床数据的回顾性分析.
- 根据CD5的表达,患者被分为CD5+和CD5组.
- 进行了统计分析,以比较临床特征和生存结果.
主要成果:
- 与CD5患者相比,CD5+DLBCL患者的年龄较大 (中位数为62岁与56岁),女性患者的频率更高 (62.96%与41.79%).
- 较高比例的CD5+患者的国际预后指数 (IPI) 评分>2 (62.96%对40.30%).
- CD5+DLBCL显示中位数整体存活时间 (27 vs. 30 个月) 和无进展存活时间 (31 vs. 32.5 个月) 显著较短.
结论:
- 与CD5+DLBCL相比,CD5+DLBCL与更差的预后有关.与CD5-DLBCL相比,DLBCL与更差的预后有关.
- CD5+DLBCL的特点是女性患病率较高,年龄较大,IPI得分较高.
- CD5+DLBCL是一种独特的亚型,需要特别的临床考虑.
更多相关视频
09:08Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
5.4K
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
13.7K
相关概念视频
01:21Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
02:07Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K